Bruno Sangro

Bruno Sangro's AcademicInfluence.com Rankings

Bruno Sangro

Computer Science

#5485

World Rank

#5793

Historical Rank

Artificial Intelligence

#1714

World Rank

#1746

Historical Rank

Database

#2638

World Rank

#2760

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Bruno Sangro Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bruno Sangro's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (2017) (2764)
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. (2015) (1463)
Hepatocellular carcinoma (2016) (1162)
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. (2016) (878)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. (2013) (798)
Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation (2011) (573)
Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions (2012) (554)
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) (2019) (535)
BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update (2021) (499)
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. (2011) (490)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020) (433)
Immunological landscape and immunotherapy of hepatocellular carcinoma (2015) (425)
New therapies for hepatocellular carcinoma (2006) (388)
Liver disease induced by radioembolization of liver tumors (2008) (332)
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. (2004) (307)
Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. (2003) (290)
Radioembolization for hepatocellular carcinoma. (2012) (283)
Advances in immunotherapy for hepatocellular carcinoma (2021) (277)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (263)
Prognostic factors and prevention of radioembolization‐induced liver disease (2013) (241)
Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. (2009) (237)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. (2021) (230)
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. (2015) (219)
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. (2005) (211)
Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. (2012) (208)
Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. (2006) (204)
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. (2019) (191)
Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrom (1996) (191)
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2019) (187)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (185)
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. (2005) (185)
A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. (2003) (180)
Research reporting standards for radioembolization of hepatic malignancies. (2011) (180)
Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins (2014) (180)
Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma (2001) (178)
Transjugular intrahepatic portal‐systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters (1995) (173)
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes (2017) (169)
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma (2020) (167)
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. (2017) (159)
Partial splenic embolization for the treatment of hypersplenism in cirrhosis (1993) (156)
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives (2013) (153)
De Novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival (2005) (149)
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation (2012) (147)
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade (2016) (141)
The Role of Thrombopoietin in the Thrombocytopenia of Patients with Liver Cirrhosis (2005) (137)
Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. (2010) (136)
Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas (1999) (136)
Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90 (2013) (135)
Hepatitis B and C viral infections in patients with hepatocellular carcinoma (1992) (132)
Liver transplantation in patients with hepatocellular carcinoma across Milan criteria (2008) (131)
Targets for immunotherapy of liver cancer. (2017) (131)
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022) (130)
Systemic treatment of hepatocellular carcinoma. An EASL position paper. (2021) (128)
Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution (2016) (128)
Gastroduodenal Injury After Radioembolization of Hepatic Tumors (2007) (126)
Radioembolization for the Treatment of Liver Tumors: General Principles (2012) (122)
Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. (1999) (122)
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma (2015) (122)
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (2021) (122)
Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8 (2005) (116)
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality (2021) (114)
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. (2016) (114)
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. (2020) (113)
Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. (2012) (112)
Liver Transplant Recipients Older Than 60 Years Have Lower Survival and Higher Incidence of Malignancy (2003) (110)
Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. (2001) (109)
A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma (2010) (109)
Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 (2001) (97)
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (2022) (96)
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2020) (95)
Radioembolization for Hepatocellular Carcinoma: A Review of the Evidence and Treatment Recommendations (2011) (95)
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model (2013) (94)
Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal (2011) (87)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (87)
Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. (1997) (87)
Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. (2004) (86)
Gene therapy of cancer based on interleukin 12. (2005) (86)
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. (2005) (86)
Totally Laparoscopic Right‐Lobe Hepatectomy for Adult Living Donor Liver Transplantation: Useful Strategies to Enhance Safety (2013) (86)
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis (2019) (85)
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. (2013) (85)
Biocompatibility, Inflammatory Response, and Recannalization Characteristics of Nonradioactive Resin Microspheres: Histological Findings (2009) (83)
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. (2019) (83)
No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. (2012) (82)
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (81)
Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance (2013) (80)
Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review (2017) (80)
A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. (2018) (79)
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC (2015) (78)
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model (2018) (78)
CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. (2021) (76)
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. (2017) (76)
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres (2021) (76)
Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (75)
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach (2019) (75)
Nonmelanoma skin cancer after liver transplantation. Study of risk factors (2005) (73)
Medical treatment for cholangiocarcinoma (2019) (72)
Color Doppler-US guidance in transjugular placement of intrahepatic portosystemic shunts. (1992) (72)
Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. (2011) (71)
Transarterial Chemoembolization and Radioembolization (2014) (70)
The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. (2017) (69)
General Selection Criteria of Patients for Radioembolization of Liver Tumors: An International Working Group Report (2011) (69)
Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. (2014) (67)
Spontaneous regression of hepatocellular carcinoma: a systematic review (2009) (66)
Herpes zoster after liver transplantation: Incidence, risk factors, and complications (2004) (64)
A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. (2016) (64)
Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages (2011) (60)
Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients (2011) (60)
Transarterial therapies for hepatocellular carcinoma (2011) (60)
Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. (2008) (59)
Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. (2002) (59)
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. (2010) (59)
A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. (2009) (58)
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion (2017) (57)
Safety and Efficacy Assessment of Flow Redistribution by Occlusion of Intrahepatic Vessels Prior to Radioembolization in the Treatment of Liver Tumors (2010) (57)
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events (2018) (56)
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. (2019) (56)
Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. (2009) (54)
Plasma levels of substance p in liver cirrhosis: Relationship to the activation of vasopressor systems and urinary sodium excretion (1995) (54)
Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. (2010) (54)
Spontaneous Regression of Hepatocellular Carcinoma: Three Case Reports and a Categorized Review of the Literature (2009) (53)
Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report (2009) (51)
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib (2016) (51)
Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. (1998) (50)
Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation (2015) (50)
Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12 (2001) (50)
Liver changes in patients with hyperthyroidism. (2008) (48)
Liver transplantation in cirrhotic patients with diabetes mellitus: Midterm results, survival, and adverse events (2001) (47)
Totally Laparoscopic Right Hepatectomy for Living Donor Liver Transplantation: Analysis of a Preliminary Experience on 5 Consecutive Cases (2017) (45)
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. (2018) (45)
Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib (2012) (44)
Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. (2003) (43)
Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells (2018) (43)
Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity (2014) (42)
Radioembolization in the Treatment of Unresectable Liver Tumors: Experience Across a Range of Primary Cancers (2012) (41)
The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres (2017) (40)
Gene therapy of liver cancer. (2006) (40)
Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study. (2016) (40)
[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. (2016) (40)
Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies (2002) (40)
Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins (2019) (40)
Liver damage using suicide genes. A model for oval cell activation. (2000) (38)
Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis (2020) (38)
The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort (2018) (38)
Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib (2017) (37)
Prognostic model for early acute rejection after liver transplantation (2001) (37)
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials (2018) (37)
The promise of gene therapy in gastrointestinal and liver diseases (2003) (37)
Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation. (2012) (37)
Treatment of Hepatocellular Carcinoma by Radioembolization Using 90Y Microspheres (2009) (36)
Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study. (2016) (35)
Tracing transgene expression in cancer gene therapy: a requirement for rational progress in the field. (2002) (33)
Efficacy and Toxicity of Intra-Arterial Cisplatin and Etoposide for Advanced Hepatocellular Carcinoma (2002) (33)
The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis (2019) (33)
Milestones in the pathogenesis and management of primary liver cancer. (2020) (33)
Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging. (2004) (32)
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (2020) (32)
Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. (2017) (32)
Integrating Radioembolization into the Treatment Paradigm for Metastatic Neuroendocrine Tumors in the Liver (2012) (31)
Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. (2020) (31)
Liver cancer arterial perfusion modelling and CFD boundary conditions methodology: a case study of the haemodynamics of a patient‐specific hepatic artery in literature‐based healthy and tumour‐bearing liver scenarios (2016) (29)
[Diagnosis of small hepatocellular carcinoma]. (2007) (29)
Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT) (2020) (29)
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. (2021) (28)
Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells (2017) (28)
Gene therapy of liver diseases (2004) (28)
Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study. (2017) (28)
Assessing the impact of COVID-19 on liver cancer management (CERO-19) (2021) (28)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma (2021) (27)
Risk factors for recurrence of hepatitis C after liver transplantation. (1998) (27)
Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach (2020) (26)
Identification of coding and long non-coding RNAs differentially expressed in tumors and preferentially expressed in healthy tissues. (2019) (25)
Chemoembolization and radioembolization. (2014) (25)
Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. (2017) (24)
Hyperhomocysteinemia in liver transplant recipients: Prevalence and multivariate analysis of predisposing factors (2000) (24)
CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (24)
A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma (2011) (23)
Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus. (2003) (23)
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. (2020) (23)
Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors: Introduction to the International Working Group Report (2012) (22)
Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. (2013) (21)
Assessment of the Hong Kong Liver Cancer Staging System in Europe (2016) (21)
Gene Therapy of Hepatocellular Carcinoma and Gastrointestinal Tumors (2002) (21)
Factors related to increased resting energy expenditure in men with liver cirrhosis (2015) (21)
P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1 (2020) (20)
Effectiveness of aprotinin in orthotopic liver transplantation. (1993) (20)
Computational particle–haemodynamics analysis of liver radioembolization pretreatment as an actual treatment surrogate (2017) (20)
Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases (2012) (19)
Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin. (1986) (19)
Gene therapy for liver cancer: clinical experience and future prospects. (2010) (19)
Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis. (2013) (19)
Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? (2009) (19)
Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients. (2017) (19)
Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures (2021) (19)
The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma (2021) (18)
Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo (2011) (18)
Gene therapy of neoplastic liver diseases. (2003) (18)
Partial splenic embolization in the treatment of thrombocytopenia after liver transplantation. (1997) (18)
Agenesis of the dorsal pancreas: systematic review of a clinical challenge. (2016) (18)
NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma (2017) (18)
Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma (2021) (17)
Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection (2015) (17)
Immune monitoring of immunosuppression withdrawal of liver transplant recipients. (2015) (17)
Renal biopsy with forceps through the femoral vein. (1995) (17)
Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation. (2017) (17)
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma (2022) (16)
Radioembolization for Hepatocellular Carcinoma: Evidence-Based Answers to Frequently Asked Questions (2011) (16)
The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer (2016) (16)
Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma. (2022) (15)
Computational assessment of the effects of the catheter type on particle-hemodynamics during liver radioembolization. (2016) (15)
Increased liver stiffness values in patients with heart failure. (2013) (15)
Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. (2020) (15)
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial (final report Maag Lever Darm Stichting projectno. WS 00???78 (WS 97/87)) (2006) (14)
The role of angled‐tip microcatheter and microsphere injection velocity in liver radioembolization: A computational particle–hemodynamics study (2017) (14)
Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma (2020) (14)
Liver transplantation in cirrhotic patients over 60 years of age. (1998) (14)
Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth (2017) (14)
Liver Radioembolization: An Analysis of Parameters that Influence the Catheter-Based Particle-Delivery via CFD. (2018) (14)
Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells. (2011) (14)
Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK (2015) (13)
Subsequent nonmelanoma skin cancer after liver transplantation. (2012) (13)
Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies (2018) (13)
Abstract 4387: Antiviral and antitumoral effects of the anti-CTLA4 agent tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: Results from a phase II clinical trial (2012) (13)
Gene Therapy of Hepatocellular Carcinoma (2002) (13)
Nonsurgical Treatment for Localized Hepatocellular Carcinoma (2014) (13)
Cancer Immunotherapy Principles and Practice (2018) (13)
A proof-of-concept study of the in-vivo validation of a computational fluid dynamics model of personalized radioembolization (2021) (12)
[Comparison of the M and XL FibroScan(®) probes to estimate liver stiffness by transient elastography]. (2014) (12)
The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis (2020) (12)
The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective (2021) (12)
Numerical investigation of liver radioembolization via computational particle-hemodynamics: The role of the microcatheter distal direction and microsphere injection point and velocity. (2016) (12)
The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. (2020) (12)
Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma (2020) (12)
New strategies to enhance gene therapy efficiency. (2002) (12)
Other clinical studyTransjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters☆ (1995) (12)
International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis (2020) (12)
Idiopathic adulthood ductopenia: long-term follow-up after liver transplantation. (2001) (12)
Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease. (1995) (11)
Refined tools for the treatment of hepatocellular carcinoma. (2005) (11)
Numerical zero‐dimensional hepatic artery hemodynamics model for balloon‐occluded transarterial chemoembolization (2018) (11)
Future therapies for hepatocellular carcinoma. (2005) (10)
Ribavirin in desquamative interstitial pneumonia. (1988) (10)
Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040 (2017) (10)
Physiological outflow boundary conditions methodology for small arteries with multiple outlets: A patient-specific hepatic artery haemodynamics case study (2015) (10)
Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France (2020) (10)
Biologic therapy of liver tumors. (2004) (9)
Nivolumab in sorafenib-naive and - experienced patients with advanced hepatocellular carcinoma (HCC): checkMate 040 study (2017) (9)
Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel (2017) (9)
A phase I clinical trial of intratumoral injection of adenovirus encoding interleukin-12 in patients with hepatocellular carcinoma and other advanced gastrointestinal tumors (2003) (9)
Liver Radioembolization Using 90Y Resin Microspheres in Elderly Patients: Tolerance and Outcome (2010) (9)
Neoantigens as potential vaccines in hepatocellular carcinoma (2022) (9)
Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. (1998) (9)
Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. (2021) (9)
Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. (2017) (9)
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial (2021) (9)
Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study (2018) (9)
Evaluation of the rabbit liver by direct portography and contrast-enhanced computed tomography: anatomical variations of the portal system and hepatic volume quantification (2017) (9)
Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. (2021) (9)
Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC). (2016) (8)
CONVERSION FROM CYCLOSPORINE A TO MYCOPHENOLATE MOFETIL IN LIVER TRANSPLANT RECIPIENTS WITH RENAL FUNCTION IMPAIRMENT (1998) (8)
Splicing Factor SLU7 Prevents Oxidative Stress‐Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage (2021) (8)
O110 AN INTERNATIONAL COLLABORATIVE STUDY ASSESSING THE ROLE OF AETIOLOGY AND STAGE IN SURVIVAL IN HCC – IMPLICATIONS FOR SCREENING (2014) (8)
Gene therapy of liver cancer. (2006) (8)
Abstract 3183: Initial safety of AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma (2019) (8)
Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study (2017) (8)
A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts). (2019) (7)
Whole body 18fluoro-l-dopa PET–CT: a useful tool for location and surgical guidance in primary carcinoid tumours (2008) (7)
[Fatal pulmonary embolism after embolization of a hepatocellular carcinoma using microspheres]. (2008) (7)
Hepatic Flow Redistribution is Feasible in Patients with Hepatic Malignancies Undergoing Same-Day Work-Up Angiography and Yttrium-90 Microsphere Radioembolization (2019) (7)
Felty's syndrome: Response to cyclosporin A with disappearance of neutrophil autoantiboidies (1991) (7)
[Treatment of chronic hepatitis B virus infection]. (2004) (7)
Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage (2018) (7)
A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). (2021) (7)
114 SIRTACE: A RANDOMISED MULTICENTRE PILOT TRIAL OF SELECTIVE INTERNAL RADIOEMBOLISATION (SIRT) WITH YTTRIUM-90 MICROSPHERES VERSUS TRANSARTERIAL CHEMO-EMBOLISATION (TACE) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) (2013) (7)
Reply to: "Pre-therapeutic dosimetry evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres". (2013) (7)
Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040 (2020) (6)
Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives (2013) (6)
3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization (2021) (6)
Durvalumab as a Successful Downstaging Therapy for Liver Transplantation in Hepatocellular Carcinoma: the Importance of a Wash-Out Period. (2021) (6)
Radioembolization-Induced Liver Disease (2013) (6)
O138 PHASE 1 CLINICAL TRIAL OF LIVER DIRECTED GENE THERAPY WITH rAAV5-PBGD IN ACUTE INTERMITTENT PORPHYRIA: PRELIMINARY SAFETY DATA (2014) (6)
Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study (2020) (6)
[Spontaneous tumor regression. Report of 2 cases]. (1990) (6)
Splenic embolization prior to myelosuppressive treatment in hepatocarcinoma and active chronic hepatitis. (1992) (6)
Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. (2022) (6)
Hepatitis C virus (HCV) viremia in patients with hepatocellular carcinoma (HCC) detected by nested-PCR (1991) (6)
The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT (2020) (6)
O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma (2020) (5)
Stakeholder perspectives on European priorities for comprehensive liver cancer control: a conjoint analysis. (2013) (5)
Evaluation of sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma. (2011) (5)
[Survival benefit with intraarterial techniques in hepatocellular carcinoma]. (2014) (5)
[Diagnosis and treatment of hepatocellular carcinoma]. (2009) (5)
Abstract 2675: Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040 (2019) (5)
Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy (2020) (5)
Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure (2013) (5)
Transvenous liver biopsy in patients with cirrhosis with use of the femoral venous approach and a flexible forceps. (1994) (5)
P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073 (2021) (5)
Long Noncoding RNA EGOT Responds to Stress Signals to Regulate Cell Inflammation and Growth (2021) (5)
The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort. (2018) (5)
European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres. (2010) (5)
Usefulness of serum metabolic profiling in the search of novel diagnostic biomarkers for primary sclerosing cholangitis, intrahepatic cholangiocarcinoma and hepatocellular carcinoma (2018) (4)
FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040 (2019) (4)
1134. Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients with Metastatic Gastrointestinal Carcinomas (2005) (4)
Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH (2021) (4)
Immunotherapy of hepatocellular carcinoma. (2014) (4)
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib (2022) (4)
CFD Simulations of Radioembolization: A Proof-of-Concept Study on the Impact of the Hepatic Artery Tree Truncation (2021) (4)
In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID-19 vaccine-related hepatitis (2022) (4)
Laparotomic eventration or colonic prolapse after chemotherapy‐induced emesis (1988) (4)
268 SAFETY AND TOXICITY OF THE COMBINATION OF Y90-RADIOEMBOLIZATION AND SORAFENIB IN ADVANCED HCC: AN INTERIM ANALYSIS OF THE EUROPEAN MULTICENTER TRIAL SORAMIC (2013) (4)
Computational Fluid Dynamics Modeling of Liver Radioembolization: A Review (2021) (4)
A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy (2021) (4)
Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization (2021) (4)
Dosimetry and Dose Calculation (2013) (4)
A methodology for numerically analysing the hepatic artery haemodynamics during B-TACE: a proof of concept (2019) (4)
Tumors of the Liver and Biliary Tract (1992) (3)
Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (2020) (3)
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group (2022) (3)
219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study (2016) (3)
[Severe hepatotoxicity caused by amiodarone: description of a case]. (1999) (3)
SIRT Approval for Early HCC, What Comes Next? (2021) (3)
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming (2022) (3)
Radioembolization for hepatocellular carcinoma: gaining insight on a personalized approach (2017) (3)
Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells (2020) (3)
Results in Hepatocellular Carcinoma (2013) (3)
Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040 (2019) (3)
Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors (2018) (3)
Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer. (1987) (3)
A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL. (2020) (3)
Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience (2018) (3)
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial (2021) (3)
Aortic valve replacement with bioprostheses in liver transplant recipients. (2000) (3)
Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma (2013) (3)
Pneumatocele during sorafenib therapy: first report of an unusual complication (2017) (3)
Results of two Controlled Studies on Antiemetic Combination against Vomiting Induced by 5-Fluorouracil (1987) (3)
Selective internal radiation therapy (SIRT) using Y90 resin microspheres as consolidation treatment for liver metastases from colorectal cancer (LCRC). (2015) (3)
Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood (2022) (3)
Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study. (2014) (2)
P1318 : Phase I dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular carcinoma in patients with or without chronic viral hepatitis (2015) (2)
A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits (2022) (2)
The ENRY analysis: a 325-patient European multicentre analysis (2012) (2)
The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation (2021) (2)
A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC (2020) (2)
On the importance of spiral‐flow inflow boundary conditions when using idealized artery geometries in the analysis of liver radioembolization: A parametric study (2020) (2)
Older age and liver transplantation (2005) (2)
Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study. (2017) (2)
SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040 (2022) (2)
Radioembolisation — A New Treatment for Primary and Secondary Liver Tumours (2006) (2)
Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next? (2021) (2)
650 SURVIVAL AND TOLERABILITY FOLLOWING Y-RESIN MICROSPHERE RADIOEMBOLISATION IN PATIENTS WITH UNRESECTABLE BCLC STAGE C HEPATOCELLULAR CARCINOMA (HCC) (2011) (2)
The joint use of 99mTc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning (2021) (2)
Segmental Pneumonitis after Radioembolization. (2018) (2)
Nivolumab (Nivo) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): the CheckMate 040 Study (2016) (2)
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study (2016) (2)
Adenovirus-mediated transfer of suicide gene under control of tumor-specific promoter provides an efficient and safe vector for gene therapy of hepatocellular carcinoma (HCC) (2001) (2)
714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) (2022) (2)
P979 NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A PREDICTOR OF ONE-YEAR SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB (2014) (2)
Pneumatosis coli due to pharmacological constipation. (2007) (2)
795 PROGNOSTIC FACTORS AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED BY Y90-RADIOEMBOLIZATION (Y90-RE) (2009) (2)
The Post-Sir-Spheres Surgery Study (P4s): Liver Surgery Can Be Safely Performed In Patients With Hepatocellular Carcinoma (Hcc) Previously Treated with Selective Internal Radiation Therapy (Sirt) using Y-90 Resin Microspheres (2015) (2)
Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study (2022) (2)
Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (HCC) (SORAMIC). (2012) (2)
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial (2022) (2)
Radioembolisation in Hepatocellular Carcinoma: Principles of Management (2018) (2)
Liver function considerations for post-selective internal radiation therapy resection (hepatocellular carcinoma and metastatic colorectal cancer). (2014) (2)
Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections. (2021) (2)
[In vivo evaluation of gene transfer]. (2002) (2)
80 EUROPEAN NETWORK ON RADIOEMBOLISATION WITH 90Y-RESIN MICROSPHERES (ENRY) MULTICENTRE EVALUATION OF SURVIVAL, SAFETY AND LIVER FUNCTION FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) (2011) (2)
Assessment of radioembolization among patients who met the inclusion criteria for Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP). (2012) (2)
Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know (2019) (2)
The role of thrombopoietin on the pathogenesis of thrombocytopenia in liver cirrhosis (2003) (2)
The HDAC inhibitor belinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors in a murine hepatocellular carcinoma model (2018) (2)
Radioembolization: Concepts and Procedures (2013) (2)
Patient selection criteria for selective internal radiation therapy and integration into treatment guidelines (2012) (2)
P0118 : Phase 1–2 clinical trial in patients with decompensated liver cirrhosis treated with bone-marrow derived endothelial progenitor cells (2015) (2)
Gene therapy of primary and metastatic liver tumors. (2001) (1)
Radioembolization as an adjunct therapy to the resection of liver tumors. (2015) (1)
Treatment of hepatocellular carcinoma (HCC) with intraarterial combination chemotherapy (1991) (1)
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. (2022) (1)
The post-SIR-Spheres surgery study (P4S): analysis of outcomes following hepatic resection of patients previously treated with selective internal radiation therapy (SIRT), with or without exposure to future liver remnant (FLR) (2015) (1)
Yttrium-90 Microspheres for Other Liver Metastases (2013) (1)
Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience (2023) (1)
Pure laparoscopic major liver resection after yttrium90 radioembolization: a case-matched series analysis of feasibility and outcomes (2022) (1)
67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) (2022) (1)
Real-world outcomes of patients with intrahepatic cholangiocarcinoma treated with trans-arterial radioembolization: Results from the CIRSE Registry for SIR-Spheres Therapy (CIRT), a large European prospective multi-center observational study. (2021) (1)
From the Editor's Desk…. (2021) (1)
134 Incidence and mortality of De Novo neoplasia after liver transplantation (LT). Case-control study (2004) (1)
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis (2020) (1)
Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) – HEPAVAC (2017) (1)
SLU7 prevents oxidative stress-mediated HNF4 degradation preserving hepatic differentiation and protecting from liver damage (2021) (1)
Felty's syndrome: response to cyclosporin A with disappearance of neutrophil autoantibodies. (1991) (1)
Immunotherapy in hepatocellular carcinoma. (2022) (1)
189 EFFICACY OF TIPS FOR THE PREVENTION OF TOTAL PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS WAITING FOR LIVER TRANSPLANTATION (2012) (1)
Immunotherapy in HCC—No rush despite the hype (2022) (1)
Lessons from tips Peripheral arterial vasodilation is not the sole determinant of sodium retention in cirrhosis (1994) (1)
Rhabdomyolysis after Intentional Acetaminophen and Carbon Monoxide Poisoning (2012) (1)
Surgical Treatment and Radioembolization (2013) (1)
CASE REPORT: Idiopathic Adulthood Ductopenia (2001) (1)
Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT. (2022) (1)
Sorafenib (Sor) and mTOR inhibitors (mTORinh) combination for hepatocarcinoma recurrence after liver transplantation. (2011) (1)
In reply to Dr. Kao et al. (2011) (1)
Updated data from an ongoing study with ADP-A2AFP spear T-cells (2020) (1)
The post-SIR-spheres surgery study (P4S): influence of prior chemotherapy on survival following hepatic resection in patients with metastatic colorectal cancer previously treated with selective internal radiation therapy (SIRT) (2016) (1)
Analysis of the albumin‐bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after direct‐acting antiviral therapy (2022) (1)
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib (2022) (1)
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial (2022) (1)
Locoregional Transarterial Therapies for Hepatocellular Carcinoma: Transarterial Chemoembolization and Radioembolization (2013) (1)
Abstract 2354: Cancer vaccine development for hepatocellular carcinoma - HEPAVAC (2016) (1)
Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. (2014) (1)
357 A potential therapy for liver metastasis mediated by the inducible expression of interleukin-12 (IL-12) using gutless adenoviral vector (2004) (1)
DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis (2022) (1)
Immunotherapy in hepatocellular carcinoma - No rush despite the hype. (2022) (1)
Lymphocytes from Carcinoembryonic Antigen Identification of an Antigenic Epitope for Helper T Updated Version (2002) (1)
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study (2022) (1)
In Vitro Model for Simulating Drug Delivery during Balloon-Occluded Transarterial Chemoembolization (2021) (1)
Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease (2021) (1)
180 Results of a randomized double-blind, controlled pilot study of the administration of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis (2004) (1)
TARE ought not to borrow future liver function from patients with HCC. But does it? (2023) (0)
SAT-425-Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis (2019) (0)
1028 INCIDENCE AND RISK FACTORS OF RADIOEMBOLIZATION (RE)-INDUCED LIVER DISEASE: RESULTS OF GLOBAL THERAPEUTIC STRATEGY AIMING TO PREVENTION (2012) (0)
Abstract 2361: Big data analysis allows the identification of long non-coding RNAs with therapeutic potential against hepatocellular carcinoma (2018) (0)
Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease (2021) (0)
Serum lipidomics as diagnostic potential for metabolic-associated hepatocellular carcinoma (2021) (0)
Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. (2023) (0)
[Gene therapy: what is it and what is its use?]. (2005) (0)
Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma (2023) (0)
From the Editor’s Desk… (2021) (0)
561 FACTORS PREDICTIVE OF TOLERANCE AFTER LIVER TRANSPLANTATION (2013) (0)
Effective and safe gene therapy of experimental liver cancer by intratumoral injection of a defective adenovirus containing the thymidine kinase gene (1999) (0)
From the Editor's Desk... (2023) (0)
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association (2022) (0)
157A comparison of tacrolimus and cyclosporine microemulsion as primary immunosuppressants after liver transplantation (2000) (0)
[Gene therapy for liver diseases]. (2000) (0)
Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial (2022) (0)
Reply (2012) (0)
From the Editor's Desk (1957) (0)
808. Monitoring of Transgene Expression in Cancer Patients with Positron Emission Tomography (PET) (2005) (0)
From the Editor's Desk…. (2020) (0)
564 Spectrum of hepatobiliary disease in adults with heterozygous MDR3 deficiency (2004) (0)
Contents (2020) (0)
From the Editor's Desk... (2020) (0)
Contents (2020) (0)
Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma (2017) (0)
Subject Index Vol. 62, 2002 (2002) (0)
Results in Liver Metastatic Colorectal Cancer (2013) (0)
Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma (2017) (0)
Complete Response under Sorafenib Treatment for Hepatocellular Carcinoma is Associated to Development of Dermatology Adverse Events (2016) (0)
Pattern of progression determines post-progression survival in patients with hepatocellular carcinoma treated with Radioembolization (2018) (0)
From the Editor's Desk... (2022) (0)
From the Editor's Desk…. (2020) (0)
Computational study of a novel catheter for liver radioembolization (2022) (0)
From the Editor's Desk…. (2020) (0)
From the Editor’s Desk… (2001) (0)
Factors predicting survival after transjugular intrahepaticportosystemic shunt (TIPS) (2000) (0)
Abstract 2342: RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers (2023) (0)
O72 PHASE 1–2 CLINICAL TRIAL IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS TREATED WITH BONE-MARROW DERIVED ENDOTHELIAL PROGENITOR CELLS: PRELIMINARY SAFETY AND EFFICACY ANALYSIS (2014) (0)
Early acute rejection after liver transplantation (LT): Multivariate analysis of risk factors (2000) (0)
From the Editor's desk…. (2021) (0)
Impact of prior procedures on overall survival following radioembolization in patients with unresectable hepatocellular carcinoma (HCC). (2011) (0)
From the Editor's Desk... (2022) (0)
Risk factors for metabolic complications after liver transplantation(LT). Multivariate logistic regression analysis (2000) (0)
Subject Index Vol. 19, 2001 (2002) (0)
From the Editor’s Desk… (2020) (0)
[Antiemetic inefficacy of high intravenous doses of metoclopramide by short-term infusion in vomiting induced by antineoplastic chemotherapy]. (1986) (0)
From the Editor's Desk... (2020) (0)
Histopathologic study in transjugular intrahepatic portosystemic shunt (TIPS) (1998) (0)
412 ISOLATION AND DIFFERENTIATION OF BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH ADVANCED LIVER CIRRHOSIS FOR THERAPEUTICAL USE (2012) (0)
EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma. (2023) (0)
Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) (2023) (0)
Radioembolization for unresectable hepatocellular carcinoma (HCC) in the elderly. (2011) (0)
Combination immunotherapy for hepatocellular carcinoma. (2023) (0)
Epigenetic mechanism and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNA methyltransferase 1 for the inhibition of liver fibrosis (2020) (0)
From the Editor's Desk... (2022) (0)
Cyclophosphamide for Metastatic Cancer Combined with GM-CSF, Pegylated IFN, and Loaded with Autologous Tumor Lysates Pilot Clinical Trial of Type 1 Dendritic Cells (2011) (0)
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming (2022) (0)
From the Editor's Desk... (2022) (0)
Abstract No. 201: Survival and tolerability following 90Y-resin microsphere radioembolization in patients with unresectable BCLC stage C hepatocellular carcinoma (HCC) (2012) (0)
Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population (2020) (0)
From the Editor's Desk... (2022) (0)
Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. (2022) (0)
PS-137-A multicentric study on real-life impact of nivolumab in patients with hepatocellular carcinoma (2019) (0)
PS-043-Dual targeting of G9a and DNM-methyltransferase-1 for the treatment of experimental cholangiocarcinoma (2019) (0)
Contents Vol. 19, 2001 (2002) (0)
From the Editor's Desk... (2023) (0)
P0235 : Protein N-terminal acetylation inhibition as a novel therapeutic target for hepatocellular carcinoma (2015) (0)
P552 PROTEOMIC ANALYSIS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AFTER LIVER RADIOEMBOLIZATION. PRELIMINARY RESULTS (2014) (0)
From the Editor's Desk… (2020) (0)
Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals (2018) (0)
Computational Study of the Microsphere Concentration in Blood during Radioembolization (2022) (0)
Identification of neoantigens as potential vaccines in hepatocellular carcinoma (2020) (0)
From the Editor's Desk…. (2021) (0)
P966 EVALUATION OF THE PREVENTIVE EFFECT OF LOW DOSE ENOXAPARIN, PENTOXIFYLLINE AND URSODEOXYCHOLIC ACID TO RADIATION INDUCED LIVER TOXICITY IN A PROSPECTIVE RANDOMIZED TRIAL (2014) (0)
Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission. (2022) (0)
625. Viral Shedding after Intratumoral Injection of Adenoviral Vectors to Patients with Cancer (2006) (0)
Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers (2023) (0)
Abstract No. 117 A phase 3, double-blind, randomized study of nivolumab and Ipilimumab), nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma (2021) (0)
Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers Yet (2020) (0)
Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma (2022) (0)
[Liver enzyme elevation secondary to macroenzymes: macro-GOT]. (2013) (0)
Splenic embolization (SE) in the treatment of hypersplenism due to portal hypertension (HS-PHT) (1989) (0)
Personalized Medicine and Imaging Serum Interleukin-8 Re fl ects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins (2014) (0)
Conversion to mycophenolate mofetil (MMF) instead of cyclosporine a (CYA) in liver transplant (LT) recipients with renal function impairment. A pilot study (1998) (0)
375 LIVER RADIOEMBOLIZATION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY AND ANTITUMOR EFFECT (2008) (0)
From the Editor's Desk…. (2022) (0)
Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial (2021) (0)
FRI-462-A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis (2019) (0)
Abstract 1059: Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model (2017) (0)
Tips for portal hypertension in liver cirrhosis technic and early clinical experience utility in a liver transplantation program (1992) (0)
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study (2022) (0)
From the Editor's Desk... (2023) (0)
Case Report: Effectiveness of Lamivudine in Treatment of Acute Recurrent Hepatitis B After Liver Transplantation (1998) (0)
RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC). (2023) (0)
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial (2023) (0)
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (2023) (0)
Cancer gene therapy: the experience from clinical trials (2007) (0)
From the Editor's Desk... (2022) (0)
From the Editor's Desk…. (2020) (0)
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression (2022) (0)
From the Editor's Desk... (2021) (0)
Regresión tumoral espontánea. A propósito de dos casos (1990) (0)
SAT-454-Management of hepatocellular carcinoma in a real life multinational, longitudinal, observational study (TARGET-HCC) (2019) (0)
Contents (2020) (0)
From the Editor's Desk... (2020) (0)
Performance of the Hap Score among Patients with Hepatocellular Carcinoma Treated by Radioembolization (2016) (0)
260 Risks and benefit of diagnostic of biopsy of liver lesions before liver transplantation (2006) (0)
Impact of early acute rejection (EAR) on outcome after liver transplantation (LT) (2000) (0)
From the Editor's Desk… (2020) (0)
141 Results of liver transplantation in patients with hepatocellular carcinoma. Milan versus expanded criteria (2006) (0)
Abstract No. 200: Evaluation of safety, tolerability and overall survival following whole-liver, lobar or segmental radioembolization in unresectable hepatocellular carcinoma (HCC) (2012) (0)
Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis (2022) (0)
Contents Vol. 62, 2002 (2002) (0)
Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study. (2023) (0)
From the Editor's Desk... (2023) (0)
How Could 90Y-Loaded Microsphere Distribution Be Optimized? (2022) (0)
O052 : Assessment of the hong kong liver cancer staging system in europe (2015) (0)
P-130 Real-world outcomes of patients with colorectal liver metastases treated with transarterial radioembolization: Results from CIRT, a large European, prospective multi-centre, observational study (2021) (0)
928 Insulin-like growth factor-I (IGF-I) therapy in patients with advanced liver cirrhosis. Results of a randomized double-blind, controlled pilot study (2003) (0)
From the Editor’s Desk… (2022) (0)
Abstract IA25: Targeted therapies for hepatocellular carcinoma (2017) (0)
Serum interleukin-8 and its relationship to tumor burden and treatment response across malignancies of multiple tissue origins. (2014) (0)
Contents, Vol. 25, 1995 (1995) (0)
Positron emission tomography (PET) imaging of AdCMVTk biodistributionin ortothopic hepatocellular carcinoma gene therapy (2002) (0)
From the Editor’s Desk… (2001) (0)
1056 COMPARISON OF TWO DIFFERENT PROBES FOR TRANSIENT ELASTOGRAPHY FOR THE EVALUATION OF LIVER STIFFNESS (2012) (0)
From the Editor's Desk... (2021) (0)
Minimally invasive liver surgery for hepatocellular carcinoma in patients with portal hypertension (2023) (0)
Engineering tumor specific replicating adenovirus as therapeutic agent for treatment of hepatocellular carcinoma (HCC) (2003) (0)
P-17 Real-life use and long-term effectiveness results from CIREL – the multi-centre, observational study on irinotecan-eluting transarterial chemoembolization in CRLM (2022) (0)
Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant®): HEPAVAC (2016) (0)
Reply to: "Toxicity and dosimetry in SORAMIC study": Y90 radioembolization is less about tumor dose, but preserving liver function: SIRT should mimic selective techniques as employed in TACE. (2020) (0)
From the Editor's Desk... (2022) (0)
Abstract A115: Cancer vaccine development for hepatocellular carcinoma – HEPAVAC (2016) (0)
Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884]. (2020) (0)
Selective internal radiation therapy (SIRT) of inoperable primary and metastatic hepatic tumors with 90-Yttrium microspheres (SIR-Spheres(R)) (2006) (0)
From the Editor's Desk... (2021) (0)
DNA methylation regulates lncRNAs compromising hepatic identity during hepatocarcinogenesis (2022) (0)
Downstaging to liver resection by radioembolization: a difficult to reach strategy? Author reply. (2013) (0)
From the Editor's Desk…. (2020) (0)
Assesment of extrahepatic dissemination (EHD)among patients with hepatocellular carcinoma (HCC) and long survival after treatment (1991) (0)
Dual inhibition of DNA methyltransferase 1 and the histone methyltransferase G9a as a new therapeutic strategy in hepatoblastoma (2020) (0)
THU-468-SLU7 controls genome integrity: New role of truncated SRSF3 proteins (2019) (0)
Tu1483 - Hepatic Safety and Biomarker Assessments in Sorafenibexperienced Patients with Advanced Hepatocellular Carcinoma Treated with Nivolumab in the Checkmate-040 Study (2018) (0)
Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study (Preprint) (2019) (0)
Contents (2020) (0)
From the Editor's Desk... (2021) (0)
Novel role of amphiregulin in bile acids metabolism and protection from cholestatic liver injury (2018) (0)
From the Editor's Desk... (2021) (0)
Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (2020) (0)
The inhibition of the epigenetic efectors DNMT1 and G9a as a potential therapeutic strategy against the non-alcoholic fatty liver development (2022) (0)
Yttrium-90 PET/CT for the assessment of post-treatment microspheres biodistribution (2013) (0)
From the Editor's Desk…. (2021) (0)
From the Editor's Desk... (2022) (0)
Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma (2013) (0)
Survival After Intra-Arterial Treatment for Hepatocellular Carcinoma: Impact of Liver Dysfunction and Development of a Predictive Statistical Model: an International Collaborative Project (2015) (0)
Description of a novel MDR3 gene mutation causing juvenil cholelithiasis, cholelithiasis of pregnancy and adulthood biliary cirrhosis. A family study (2003) (0)
Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial (2022) (0)
hepatic vein involvement in hepatocellular carcinoma : its disappearance with intra-arterial chemotherapy (1991) (0)
252PSERUM INTERLEUKIN-8 REFLECTS TUMOR BURDEN AND TREATMENT RESPONSE ACROSS MALIGNANCIES OF MULTIPLE TISSUE ORIGINS. (2014) (0)
Subject Index Vol. 25, 1995 (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bruno Sangro?

Bruno Sangro is affiliated with the following schools:

Complutense University of Madrid
University of Navarra

Bruno Sangro's Academic­Influence.com Rankings

Why Is Bruno Sangro Influential?

Bruno Sangro's Published Works

Published Works

What Schools Are Affiliated With Bruno Sangro?

Bruno Sangro's AcademicInfluence.com Rankings